IO Biotech announced it will disclose the topline results of its Phase 3 trial for the cancer vaccine Cylembio on August 11, 2025. The trial compares Cylembio with pembrolizumab vs. pembrolizumab alone for melanoma treatment. A webcast and conference call will take place at 8:30 AM ET on August 11, 2025, to discuss the results. IO Biotech is a biopharmaceutical company focusing on developing cancer vaccines based on its T-win platform. The company’s lead candidate, Cylembio, has shown positive results in clinical trials for treating advanced melanoma. Contact information for investors and media is provided.

Read more at GlobeNewswire: IO Biotech to Announce Topline Results of Pivotal Phase 3